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Abstract
The lack of an effective TB vaccine hinders current efforts in combating the TB pandemic. One theory as to why BCG is less
protective in tropical countries is that exposure to non-tuberculous mycobacteria (NTM) reduces BCG efficacy. There are
currently several new TB vaccines in clinical trials, and NTM exposure may also be relevant in this context. NTM exposure
cannot be accurately evaluated in the absence of specific antigens; those which are known to be present in NTM and absent
from M. tuberculosis and BCG. We therefore used a bioinformatic pipeline to define proteins which are present in common
NTM and absent from the M. tuberculosis complex, using protein BLAST, TBLASTN and a short sequence protein BLAST to
ensure the specificity of this process. We then assessed immune responses to these proteins, in healthy South Africans and
in patients from the United Kingdom and United States with documented exposure to NTM. Low level responses were
detected to a cluster of proteins from the mammalian cell entry family, and to a cluster of hypothetical proteins, using ex
vivo ELISpot and a 6 day proliferation assay. These early findings may provide a basis for characterising exposure to NTM at a
population level, which has applications in the field of TB vaccine design as well as in the development of diagnostic tests.
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Introduction
Tuberculosis (TB) remains a major threat to global public
health, with an estimated 9.27 million new cases occurring
worldwide in 2007 [1]. TB incidence rates are particularly high in
countries with a high HIV prevalence, and South Africa alone
accounts for 25% of the worldwide HIV-associated TB burden
[2]. Increasing rates of drug resistance add to the difficulty of
treatment, particularly in resource-poor settings. An effective TB
vaccine would represent the most cost-effective approach to global
TB control [3]; there are currently several new candidate TB
vaccines under development.
BCG is currently the only licensed TB vaccine. It protects
against severe forms of the disease in childhood, but has very poor
efficacy in preventing adult pulmonary TB where it is most
needed, in tropical countries which have a high incidence of TB.
Protection ranges from 80% in the UK [4] to 0% in Malawi [5];
41% of this variability has been attributed to the latitude at which
the study was conducted [6].
One theory as to why BCG works less well in the tropics than in
temperate regions is exposure to non-tuberculous mycobacteria
(NTM) [7]. Animal models have shown that mice exposed to M.
avium had a reduced protective immune response to subsequent
BCG vaccination, cleared the live BCG vaccine more rapidly than
mice not exposed to M. avium, and were more susceptible to M.
tuberculosis infection following BCG vaccination [8]. A model in
which M. avium was administered after BCG vaccination showed
declining efficacy of BCG with ongoing exposure to M. avium [9].
Conversely, other animal models have shown partial protection
against M. tuberculosis infection following NTM exposure [10,11],
and variations in dose [12], species [8] and strain [11,13] of
infecting NTM or of M. tuberculosis [14] have been shown to
influence whether NTM exposure interferes with BCG efficacy or
contributes towards protection against M. tuberculosis. It is not
known whether, if exposure to NTM has an effect on the efficacy
of BCG, this is caused by those antigens common to both BCG
and NTM (which may provide a cross-protective effect), or by
those antigens which are present in NTM but not in BCG (which
could produce an antagonistic effect).
In humans, Black et al have shown that adolescents living in
Malawi had marked pre-existing T cell responses to purified
protein derivative (PPD) prior to BCG vaccination. After
vaccination with BCG the increase in response to PPD was
minimal, in contrast to adolescents in the UK, in whom baseline
responses were very low and a marked increase in PPD-specific
responses post BCG-vaccination was detected [15]. These pre-
vaccination immune responses to PPD were attributed to NTM
exposure; the most likely explanation, given that individuals were
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BCG naı¨ve, and those with a tuberculin skin test result suggestive
of TB exposure had been excluded from the study.
It is, however, hard to characterise NTM exposure with
certainty, as there are currently no defined antigens which are
specific to NTM and not also present in (and therefore confounded
by exposure to) M. tuberculosis and BCG. Although previous studies
have investigated NTM exposure using PPD derived from NTM
species [16], approximately 80% of proteins are shared between
PPDs of different species of NTM and M tuberculosis, so it is hard
to definitively attribute an immune response to any particular
species.
Further, the nature of the T cell response necessary for
protection against mycobacterial infection is not known: a limited
number of strong responses to critical epitopes or antigens may be
required; alternatively multiple low affinity T cell responses to
various antigens may provide protection, including cross-species
protection.
If exposure to NTM has an effect on BCG replication and
hence immunogenicity and protective efficacy, this effect might
also be seen with novel TB vaccines based on BCG. Viral vectored
and protein/ adjuvant subunit vaccines do not replicate, so may
not be susceptible to interference by this mechanism [8]. It will be
important in the development of new TB vaccines to ensure that
their efficacy is not reduced by exposure to NTM, and in order to
do this, specific measures of NTM exposure are needed. NTM-
specific antigens could also be of diagnostic use to the veterinary
and medical fields. NTM infections (for example, M. paratubercu-
losis) cause considerable morbidity and economic losses in animal
husbandry [17] and also cause human disease in certain situations.
In this study, we aimed to define antigens which are specific to
NTM (i.e. not present in the M. tuberculosis complex), and which
could be used to study NTM exposure with a high degree of
specificity. This is relevant for studies both of BCG efficacy and of
novel TB vaccines currently in development. We used a
bioinformatic approach to define families of proteins which are
present in common NTM and not in the M. tuberculosis complex,
and investigated the T cell immune response to these antigens in
patients in the UK and US who had been exposed to NTM, in
cord blood samples with a low chance of NTM exposure, and in
healthy South Africans from the Western Cape, an area with
documented NTM exposure [18].
Methods
Bioinformatic methods
All available mycobacterial genome and reference protein
sequences were downloaded from the National Center for
Biotechnology Information (NCBI) and Sanger websites on 2
December 2009 and stored in a BioSql database [19,20,21].
Sequence information from our Illumina GAIIx next generation
sequencing of a M. fortuitum isolate (isolate submitted to ATCC, ID
awaited, sequence uploaded to NCBI, ID awaited), was also
loaded into the database. Mycobacterial species were classified
into 3 groups: group 1= NTM species of interest, group 2=M.
tuberculosis complex, group 3= all other mycobacterial species
(Table 1). NTM species of interest were defined as those reported
to be frequently isolated in environmental and clinical studies from
the UK and South Africa [18,22,23,24,25,26,27]. The Prodigal
tool (v1.1), which performs well in high GC content genomes, was
used to predict open reading frames and protein sequences on all
incomplete and un-annotated genomes [28,29].
NCBI protein BLAST was used to compare all protein
sequences in the database against each other using NCBI default
parameters [30]. This approach was validated by demonstrating
identification of the M. tuberculosis-specific RD1 gene products [31]
from a BLASTP comparison of predicted proteins from M.
tuberculosis CDC1551 and M. bovis BCG (data not shown).
A protein was selected if present in at least 3 other species from
group 1 (NTM of interest) and absent from group 2 (M. tuberculosis
complex). Selected proteins were subsequently compared with all
group 2 mycobacterial genome sequences using TBLASTN, and
excluded if significant matches were found. NCBI BLASTClust
Table 1. Genome sequences downloaded.
Group 1: NTM of interest Group 2: M. tuberculosis complex Group 3: Other mycobacteria
M. avium 104 M. tuberculosis6 M. gilvum
M avium paratuberculosis K10 M. africanum1,7 M. leprae10
M. intracellulare1,2 M. bovis8 M. marinum
M. kansasii1,3 M. bovis BCG9 M. smegmatis
M. fortuitum4 M. ulcerans
M. absessus5 M. vanbaalenii
Mycobacterium JLS
Mycobacterium KMS
Mycobacterium MCS
These genome sequences were downloaded from the NCBI website [37], unless otherwise stated. Sequences are divided into NTM of interest (group one), M.
tuberculosis complex (group two) and other mycobacterial species not of interest to the project.
1. Incomplete sequences,
2. M. intracellulare ATC 13950,
3. M. kansasii ATCC 12478,
4. next generation sequencing, Oxford University,
5. Genoscope,
6. M. tuberculosis CDC1551, M. tuberculosis F11, M. tuberculosis H37Ra, M. tuberculosis H37Rv sequences,
7. Sanger website[38],
8. M. bovis AF2122/97,
9. M. bovis BCG str. Pasteur 1173P2, M. bovis BCG [Fiocruz - FAP],
10. M. leprae Br4923, M. leprae TN.
doi:10.1371/journal.pone.0026434.t001
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[32] was used to arrange the selected proteins into clusters.
Following optimisation on known families, $50% identity over
$50% length cut-offs were selected. The predicted cellular
location of clustered reference proteins were noted based on the
locateP prediction algorithm [33].
Clusters were selected for experimental testing if they: (1)
contained no proteins which hit nucleotide sequences in group 2
(M. tuberculosis complex) during TBLASTN, or (2) either (a)
contained a majority of proteins with a prediction to be secreted or
(b) contained proteins for which there was experimental evidence
of immunogenicity.
Clusters were aligned using ClustalW [34] with default
parameters, and ends were manually trimmed. This was done
because it was found that sometimes the Prodigal tool selected
initiator sites which were substantially upstream of the canonical
start site of other family members.
20-mer peptide sequences overlapping by 10 amino acids were
generated computationally. A further BLASTP was carried out
with these sequences against all bacterial reference protein
sequences. An exact hit of 9 consecutive amino acids was
considered significant. Peptides with significant hits against
members of the M. tuberculosis complex or common species of
other bacteria were excluded.
Study populations
Ethical approval was obtained from the University of Cape
Town, South Africa (REC reference 126/2006), from Oxford-
shire, UK (REC B, reference 09/H0605/75) and from Portland
VA Medical Center, Portland, United States (US) (reference
IRB00004835). Written informed consent was obtained from all
study participants. Healthy individuals living in the Western Cape,
South Africa, who were known to have a negative result to the
QuantiFERONH-TB Gold In-Tube test (Cellestis) were recruited.
An additional cohort of individuals who were known to have a
positive result was also recruited. Patients from whom NTM had
been isolated from sputum on at least 2 occasions (or at least once
from bronchoalveolar lavage) and with a low risk of TB exposure
were recruited from the Churchill Hospital, Oxford, UK, and
from Portland VA Medical Center, US. Cord blood was collected
at the John Radcliffe Hospital, Oxford, UK.
Immunology
Peptides. Peptides were dissolved in DMSO, stored at 1 mg/
ml at 220uC and used at a final DMSO concentration of
,0.35%. Pools were arranged such that each pool contained
peptides from only one cluster except in the case of very small
clusters, which were combined (Table 2).
Ex vivo IFN-c ELISpot assay. 50 ml blood was taken from
adult volunteers into sodium heparin tubes. Cord blood was taken
into a standard blood donor collection bag, containing citrate
phosphate dextrose anticoagulant. Peripheral blood mononuclear
cells (PBMC) were separated and cryopreserved from the UK
blood samples as previously described [35]; those from South
African volunteers were used immediately. PBMC were thawed
prior to use and rested overnight in 10 U/ ml benzonase nuclease
(Novagen) at 37uC 5% CO2 in a humidified incubator [35].
PBMC IFN-c responses to NTM-specific peptides (ProImmune,
UK, 20-mers overlapping by 10 amino acids, 4 mg/ml), PPD
(positive control, Statens Serum Institut, 10 mg/ml), phytohaema-
gluttinin/ phorbol 12-myristate 13-acetate (PHA/PMA, positive
control, 10 mg/ml/ 50 mg/ml) and pool of ESAT-6/ CFP-10
peptides ((negative control), 15-mers overlapping by 10 amino
acids, 4 mg/ml) were measured using overnight ex vivo ELISpot
assay. Peptides were tested in 20 pools, each pool containing
between 58 to 85 peptides. Briefly, nitrocellulose bottomed 96-well
Multiscreen HA filtration plates (Millipore, UK Ltd) were coated
with anti-human-IFN-c-mAb (Mabtech, UK) overnight at 4uC.
36105 PBMC were plated in 100 ml final volume and plates were
incubated for 18–20 h in a humidified 37uC 5% CO2 incubator
with peptide, PPD, PHA/PMA or media alone. Assays were
performed in duplicate and the results averaged. Plates were
washed and developed as previously described [35]. A plate was
considered to have passed if there were at least 200 spot forming
cells (SFC)/ 106 PBMC in at least one positive control well, and if
both negative control wells had ,20 SFC. Cut off for a positive
response was calculated as 3 median absolute deviations (MADs)
above the median.
Table 2. Protein clusters selected for the generation of peptides.
Cluster id Protein family Number of proteins/ cluster Ratio secreted prediction/ intracellular Peptide pool number
A Mce family protein 16 5 1–5
B hypothetical protein 13 5 6–7
C hypothetical protein 12 5 8,11
D hypothetical protein 8 5 9
E hypothetical protein 8 5 10
F hypothetical protein 7 4 11,12
G hypothetical protein 7 4 13
H hypothetical proteins 7 4 17
I Tat-translocated enzyme 6 4 14,15
J 27 kDa lipoprotein antigen 6 4 16
K hypothetical protein 6 4 17
L hypothetical protein 5 3 17
Protein clusters were tested in the form of overlapping peptides, shown by cluster id, protein family to which they belong, number of proteins per cluster, the ratio of
proteins with a prediction to be secreted over those predicted to be intracellular and the number of the peptide pool in which those proteins were tested. Peptide
pools 18–20 consisted of peptides which hit bacterial reference proteins with a low affinity on protein BLAST. These peptides came from all clusters, and were tested
separately from the others as there was a concern they may be less specific.
doi:10.1371/journal.pone.0026434.t002
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Proliferation assay. All cryopreserved PBMC samples from
UK-based NTM-exposed patients and cord blood samples were
analysed, where remaining cell numbers allowed [36]. Cells were
incubated with media alone or PPD (2 mg/ml), NTM-specific
peptide pool number 5, 6, 11 or 17 or ESAT-6/ CFP-10 pool (all
1 mg/ml) for 6 days at 37uC with 5% CO2. On day 3, PHA (1 mg/
ml) was added to one of the ‘media only’ wells. On day 6, PBMC
were stained with LIVE/DEAD Fixable Violet Dead Cell Stain
(Invitrogen) and fixed with BD FACS Lysing Solution (BD
Biosciences). Following permeabilisation with Perm/Wash (BD
Biosciences) cells were incubated with the following monoclonal
antibodies: anti-CD3-QDot 605, anti-CD4-APC, anti-CD8-PerCP-
Cy5.5 and anti-Ki67-PE. All antibodies were from BD Biosciences
except for CD3-QDot 605, which was from Invitrogen, and were
used in pre-determined optimal concentrations. Following washes,
samples were acquired on a BD LSRII flow cytometer (BD
Biosciences, San Jose, CA). Time gates (excluding fluctuations in
fluorescence), antibody aggregate exclusion gates and forward
scatter/ side scatter gates (selecting singlets) were followed by gating
on live CD3 positive cells, then CD4 or CD8 positive cells, then
Ki67 positive cells. Data were analysed using FlowJo Software
version 8.8.3 (Treestar Inc.) and GraphPad Prism (version 5).
Proportion of Ki67 positive was used as the readout of proliferation
[36]. A sample was considered to have passed if percentage
proliferating cells from the un-stimulated control was less than 2%,
if proliferation to either PPD or to PHAwas greater than 10% and if
proliferative responses to ESAT-6/CFP-10 peptides was less than
2%. In addition to frequency of proliferating cells, the stimulation
index was calculated as response in test well/ response in un-
stimulated well; a SI greater than 2% was considered positive.
Results
Selection of NTM-specific proteins
Fifteen complete and annotated mycobacterial genome se-
quences [37], three incomplete mycobacterial sequencing projects
[38] and 102,051 associated reference proteins [21] were available
for analysis (Table 1, Figure 1). Species were classified into 3
groups: NTM of interest (group one; isolates commonly recovered
from UK and South African clinical and environmental samples
[18,22,23,24,25,26,27]), M. tuberculosis complex (group two) and all
other mycobacterial species (group three) (Table 1).
Open reading frame prediction and M. fortuitum
sequencing
Next-generation (Illumina GAIIx) sequencing was performed on
a clinical M. fortuitum isolate, and genome assembly was undertaken
using the programme Velvet [39]. The open reading frame
prediction tool Prodigal (v1.1) [29] was applied to all contigs from
incomplete sequencing projects (including M. fortuitum), and
predicted protein sequences were derived (Figure 1). Median
predicted protein length was 243, 235, 275 and 185 amino acids for
theM. intracellulare,M. kansasii,M. africanum andM. fortuitum genomes
(median contig lengths 7888, 9278, 98,860 and 2528 respectively).
NCBI protein BLAST was used to compare all protein sequences
against themselves (see methods); 4048 group 1 proteins hit proteins
from at least 3 other mycobacterial species in group 1 genomes
(NTM species of interest), and none in group 2 (M. tuberculosis
complex). These proteins were selected for further analysis.
Clustering of mycobacterial proteins and selection of
NTM-specific proteins
BLASTClust was used to cluster these proteins into related
families. Any cluster which contained a protein that had hit a
member of the M. tuberculosis complex during the TBLASTN
process was excluded, leaving 78 clusters varying in size from 2–17
proteins. These clusters were biologically relevant, containing
families such as the Mce family, the DoxX and the 27kDa
lipoprotein antigen. From these, 12 clusters were selected for
experimental testing (Table 2). 11 were prioritised on the basis that
they were predicted to contain predominantly secreted proteins,
and one (Mce family proteins) on the basis of reports of
immunogenicity [40,41].
Stringent exclusion of peptides also present in M.
tuberculosis complex and common bacteria
Protein BLAST (see Methods) was performed on all computa-
tionally defined peptide sequences against all published bacterial
Figure 1. Bioinformatic pipeline. Summary of the steps involved in
the bioinformatic pipeline, showing numbers of sequences, hits and
clusters generated. a: hits between proteins from group 1 or 2 only
(group 3 hits excluded). BLASTP: protein BLAST, TBLASTN: BLAST of
protein sequence against 6-frame translated nucleotide sequence,
ClustalW: protein clustering tool [34].
doi:10.1371/journal.pone.0026434.g001
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reference protein sequences, resulting in 25,636 hits (Figure S1).
Peptides with hits to non-mycobacterial reference proteins were
eliminated from the process and 1699 peptides were synthesised.
T cell responses to Mce family proteins
PBMC IFN-c responses to PPD, pool of ESAT-6/ CFP-10
peptides and pools of investigational peptides were determined by
ex vivo IFN-c ELISpot assay in 9 healthy South African donors with
previous negative responses to QuantiFERONH-TB Gold In-Tube
(Figure 2). Responses to PPD were universally strong, and some of
these individuals had low level responses to the ESAT-6/ CFP-10
peptide pool. Analysing responses to NTM-specific proteins,
responses to peptide pools 5 and 6 were significantly increased
above the negative control (Wilcoxon signed rank test for matched
pairs). In addition, a broad range of individuals made responses
over the cut off, in particular to pools 3, 5 (from cluster OA, the
MCA family of proteins), 6, 7 (from cluster OB, a family of
hypothetical proteins of unknown function) and pool 8 (from
cluster OC, another family of hypothetical proteins of unknown
function). Analysing results from the South African cohorts with
negative and positive responses to QuantiFERONH-TB Gold In-
Tube together (16 individuals), there was no significant correlation
between response to any NTM-specific peptide pool and to the
ESAT-6/ CFP-10 pool of peptides (Figure S2).
IFN-c ELISpot was performed on 14 UK patients known to
have had NTM isolated from clinical specimens, using previously
frozen PBMC. In contrast with the healthy South African subjects,
these individuals had a high prevalence of co-morbidities (Table 3).
Figure 2. IFN-c ex vivo ELISpot responses to pools of NTM-specific peptides. IFN-c ex vivo ELIspot assay comparing T cell responses in PBMC
from healthy South Africans (A), NTM-exposed UK patients (B), UK cord blood samples (C) and number of responding South African healthy
volunteers to each peptide pool (D). * P = 0.06, + P= 0.02, Wilcoxon matched pairs test, comparing peptide response with unstimulated cells. No
other responses were statistically significantly different from unstimulated. Assay cut off = 3 median absolute deviations (MADs) above the median
response to unstimulated PBMC. Median response (line), interquartile range (box) and range (whiskers) shown. Cut offs were 5 (A), 17.5 (B) and 8.33
SFC/ 106 PBMC (C, Wilcoxon matched pairs test).
doi:10.1371/journal.pone.0026434.g002
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Two individuals had low level responses to the ESAT-6/ CFP-10
peptide pool and were excluded from further analysis, on the basis
of possible TB exposure in the past. Among the remaining 12, the
magnitude of response to PPD was low, and there were no
statistically significant responses to any of the experimental peptide
pools (Figure 2B). There were no statistically significant responses
to either PPD or peptide pools in the 9 ‘negative control’ cord
blood samples collected in the UK.
A 6 day proliferation assay [42], which may be more sensitive
than ex-vivo ELISpot, was performed on 18 samples from the UK
and the US; 5 were excluded for technical reasons, leaving 13 for
analysis (see Methods, Table 3). The proliferation assay used four
NTM-specific peptide pools: 5, 6, 11 and 17, chosen on the basis
of significant responses (pools 5 and 6) or borderline responses
(pools 11 and 17) detected by ELISpot (Figure 2A). There were
significant, high level proliferative responses to pools 5 and 6 in the
UK based NTM exposed patients, with 10 individuals responding
to both pool 5 and to pool 6 (Figure 3). CD8 T cell responses were
not significant, and cord blood responses were again low. The
amino acid sequences for peptides from pools 5 and 6 are shown in
Figure S3, together with the identities of the proteins making up
the clusters in these pools. Clusters A and B, from which pools 5
and 6 were derived, are shown in Figure S4.
Discussion
We used a bioinformatic pipeline to define peptides which
are shared between common NTM, eliminating peptides with
sequence homology to either the M. tuberculosis complex or to
common bacterial species. Protein BLAST was used to define an
initial shortlist of proteins which are present in at least 4 common
NTM (group 1 organisms) and not in the M. tuberculosis complex
(group 2 organisms). TBLASTN, which is independent of genome
annotation, was then used to increase the specificity of the results,
comparing protein sequences against translated nucleotide se-
quences. This was done as protein sequences derived from genome
annotation are not always experimentally confirmed, so accuracy
of annotation may vary [43]. Finally, protein BLAST excluded the
possibility of short sequence matches between NTM-specific
peptides and the M. tuberculosis complex or common bacterial
peptides. We focussed on secreted proteins since this group of
proteins is associated with the induction of strong immune
responses in mycobacteria [44,45,46,47].
Using ex vivo IFN-c ELISpot, statistically significant responses
were seen to pools 5 and 6 of the 20 NTM-specific peptide pools in
the healthy South African cohort. These pools represent the Mce
family of proteins (pool 5) and a cluster of hypothetical proteins
(pool 6, Figure 2). Additionally, a range of low-level responses was
seen to multiple other peptide pools. Although similar responses
were not detected using IFN-c ELISpot in UK NTM-exposed
patients, use of a possibly more sensitive proliferation assay
demonstrated responses to peptide pools 5 and 6 in UK and US
NTM-exposed patients. It may also be that the proliferation assay
detected a different subset of T cells such as memory cells, rather
than the effector cells that the overnight ex vivo ELISpot assay
would be expected to detect.
The immunogenic Mce (mammalian cell entry) family of
proteins are virulence factors which are involved in mycobacterial
entry and survival in macrophages [48,49]_ENREF_45. Mce
knockout mutants of M. tuberculosis have reduced virulence in mice
[50], M. bovis Mce4 induces an inflammatory response in bovine
macrophages [40] and antibodies have been demonstrated to Mce
Table 3. Clinical characteristics of patients exposed to NTM.
No. Age/years Sex Country Relevant diagnoses Organism isolated Treated? Steroids?
1 21 M UK Cystic fibrosis M kansasii, M abscessus Ya Y
2 41 F UK Bronchiectasis M fortuitum N Y
3 22 F UK Cystic fibrosis M chelonae, M abscessus Ya Yb
4 88 M UK Bronchiectasis M gordonae N N
5 28 M UK Cystic fibrosis M chelonae Y N
6 59 F UK Bronchiectasis M chelonae, M xenopi N N
7 28 M UK Cystic fibrosis M avium N N
8 37 F UK Cystic fibrosis M abscessus, M chelonae N N
9 72 M UK Bronchiectasis M chelonae, M gordonae, M
fortuitum
N Yc
10 72 F UK Bronchiectasis M intracellulare N N
11 57 F UK Bronchiectasis M avium Y N
12 75 M UK COPDd M malmoense N Y
13 27 M UK Bronchiectasis M intracellulare N N
14 76 M UK Bronchiectasis M avium Y N
MB10 76 F US Bronchiectasis M avium intracellulare Y N
MB11 65 F US Bronchiectasis M avium intracellulare Y Y
MB16 64 F US Bronchiectasis M avium intracellulare Y N
MB40 78 F US Corticosteroid use M avium intracellulare N Y
MB41 81 F US Bronchiectasis M avium intracellulare N N
Summary of the clinical characteristics of patients exposed to NTM. M=male, F = female, Y = yes, N = no, Steroids = individual taking steroids currently or within past 6
months. a. low level of adherence to prescribed treatment, b. very recent (2 doses only), c. very low dose (1 mg prednisolone per day), d. chronic obstructive pulmonary
disease.
doi:10.1371/journal.pone.0026434.t003
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proteins in TB-infected humans [41]. Importantly, the cluster of
NTM-specific Mce proteins we selected is not similar in primary
sequence to those in the M. tuberculosis complex; if it had been, these
proteins would have been excluded from the pipeline. The remaining
protein families against which immune responses were detected were
hypothetical proteins of unknown function, which are the most
frequent class of protein predicted by this, and by other similar
pipelines [51,52]. It is interesting that low-level responses were
detected to such a wide range of peptide pools in the South African
cohort. Such a pattern of responses, if present across the many
antigens shared between NTMandM. tuberculosis,might contribute to
a level of cross-protective immunity against M. tuberculosis.
It is promising that we appear to have demonstrated responses
to NTM-specific antigens. However, responses were significantly
lower than are routinely seen to immunodominant M. tuberculosis-
associated mycobacterial antigens in individuals with latent M.
tuberculosis infection. There are a number of possible explanations
for this. Unlike M. tuberculosis, NTM are not highly pathogenic.
About 80% of the predicted proteome of group 1 NTM is shared
by members of the M. tuberculosis complex, and it is possible that
these ‘core proteins’ of all mycobacteria are the most immuno-
genic. Secondly, in the absence of a gold standard test for NTM
exposure we could not determine whether all South African
volunteers had been exposed, nor how recently. The individuals in
whom we detected positive responses may have been the only
individuals with recent and significant exposure. Proliferative
studies in a larger cohort with prospective assessment of NTM
exposure might address this, although this would be associated
with significant challenges. In the absence of a defined clinical
phenotype, it remains extremely difficult to define populations of
individuals with NTM exposure, and this is a significant limitation
in the conduct of studies such as this.
Figure 3. 6 day proliferation assay responses to pools of NTM-specific peptides. Percentage Ki67 positive proliferating CD4 + lymphocytes
in UK and US NTM-exposed patients (A), UK cord blood samples (B) and number of responding UK and US patients to each peptide pool (C). Assay cut
off = stimulation index of 2%. Stimulation index = response in test well/ response in un-stimulated well.
doi:10.1371/journal.pone.0026434.g003
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Responses seen in UK and the US patients, where the exposure
was definite but the duration of the NTM exposure cannot be
quantified, were weaker than in South Africans. There are several
possible explanations for this. These individuals suffered from
chronic lung diseases, some of which are associated with low
nutritional state and immune dysregulation [53] (Table 3).
Supporting this, responses to PPD, a mixture of highly
immunogenic proteins, were low compared to levels that would
be expected in TB-exposed or recently BCG-vaccinated individ-
uals [35,54]. Additionally, assays in this group were performed on
cryopreserved cells, in which responses may be reduced [55].
Bioinformatic pipelines have been used for the purposes of
identifying antigens for the diagnosis of M. bovis infection in cattle
[51] and leprosy [56] and M. ulcerans [57] in humans. The M. bovis
pipeline consisted of a genome BLAST using the NCBI and
Tuberculist servers. Cross-reactivity occurred between M. bovis-
infected and BCG-exposed cattle, and further examination of the
individual peptides responsible for cross-reactive responses high-
lighted that cross-reacting peptides hit similar sequences from M.
tuberculosis on protein BLAST. Similarly, in the M. ulcerans pipeline,
11 out of 34 protein clusters identified using BLASTClust were
found on PCR to have previously unknown homologues in strains of
M. marinum. The M. leprae pipeline compared the M. leprae genome
and predicted protein sequences with genome and predicted protein
sequences of other published mycobacteria using BLAST and
FASTA. Proteins were recognised by T cells from patients infected
with M. tuberculosis as well as by those with leprosy [58], again
suggesting cross-reactivity. Our bioinformatic elimination of
potentially cross-reactive proteins, which was greatly aided by the
increasing availability of NTM sequence data, appears to have
achieved high levels of specificity. Of note, ESAT-6 and CFP-10 are
present in M. kansasii, M. szulgai and M. marinum, but these species
were not isolated from samples from any of the UK or US patients;
we do not know which species the South Africans were exposed to.
In conclusion, we used a novel, comprehensive and stringent
approach to define clusters of proteins which are predicted to be
secreted and are present in common species of NTM but absent
from M. tuberculosis, BCG and other members of the M. tuberculosis
complex. In South Africans, we detected low level T cell responses
to multiple proteins, including the Mce family of proteins, which
are virulence factors in mycobacteria. Mce proteins and a pool
from a cluster of hypothetical proteins were also recognised using a
proliferation assay on PBMC from UK and US patients with
NTM isolated from sputum samples. Further exploration of this
approach is warranted, and the specificity of these promising pools
could be confirmed by investigating larger cohorts of individuals
from rural tropical areas with NTM exposure defined by
surrogates such as strong PPD responses in the absence of any
response to RD1 antigens such as ESAT-6 / CFP-10.
Supporting Information
Figure S1 Peptide ‘hits’ on bacterial reference proteins
following Protein BLAST. Protein BLAST was carried out on
all peptide sequences against all bacterial reference proteins. The
resulting hits are shown by bacterial genus. Y axis: median number
peptide hits per genus. X axis: bacterial genus.
(TIF)
Figure S2 Correlation between response to ESAT-6/
CFP-10 peptide pool and NTM-specific peptide pools.
Correlation between response to pool of ESAT-6/ CFP-10
peptides and NTM-specific peptide pools, in all healthy South
African volunteers.
(TIF)
Figure S3 Peptide pools 5 and 6: constituent proteins
and peptides. Showing the identities of proteins making up the
clusters in pools 5 and 6, and the amino acid sequences for the
peptides derived from them.
(PDF)
Figure S4 Protein clusters to which immune responses
were detected using ex vivo ELISpot and proliferation
assays. A. Protein sequences making up cluster A: NP_960785.1:
hypothetical protein MAP1851 [Mycobacterium avium subsp.
paratuberculosis K-10], YP_881588.1: mce related protein
[Mycobacterium avium 104], NZ_ABIN01000058_P_11090:
predicted protein sequence from M. intracellulare genome,
YP_001852130.1: Mce protein, Mce5A [Mycobacterium mari-
num M], YP_907368.1: Mce protein, Mce5A [Mycobacterium
ulcerans Agy99], NOTNCBI_FOR1052_P_8286: predicted pro-
tein sequence from M. fortuitum genome, YP_879398.1: mce
related protein [Mycobacterium avium 104], NP_959042.1:
hypothetical protein MAP0108 [Mycobacterium avium subsp.
paratuberculosis K-10], NZ_ABIN01000014_P_12211: predicted
protein sequence from M. intracellulare genome, YP_001705239.1:
putative Mce family protein [Mycobacterium abscessus ATCC
19977], YP_001701754.1: putative MCE family protein [Myco-
bacterium abscessus ATCC 19977], YP_001705291.1: putative
Mce family protein [Mycobacterium abscessus ATCC 19977],
YP_001848502.1: MCE-family protein Mce6A [Mycobacterium
marinum M], YP_908277.1: MCE-family protein Mce6A [My-
cobacterium ulcerans Agy99], YP_001702434.1: putative Mce
family protein [Mycobacterium abscessus ATCC 19977],
YP_001705322.1: putative Mce family protein [Mycobacterium
abscessus ATCC 19977]. B. Protein sequences making up cluster
B: YP_001852137.1: hypothetical protein MMAR_3871 [Myco-
bacterium marinum M], YP_907374.1: hypothetical protein
MUL_3803 [Mycobacterium ulcerans Agy99], NP_960792.1:
hypothetical protein MAP1858 [Mycobacterium avium subsp.
paratuberculosis K-10], YP_881582.1: hypothetical protein
MAV_2381 [Mycobacterium avium 104], NZ_ABIN01000058_
P_11097: predicted protein sequence from M. intracellulare genome,
YP_001848485.1: hypothetical protein MMAR_0160 [Mycobac-
terium marinum M], YP_908294.1: hypothetical protein MUL_
4936 [Mycobacterium ulcerans Agy99], YP_001701747.1: hypo-
thetical protein MAB_1003c [Mycobacterium abscessus ATCC
19977], NP_959049.1: hypothetical protein MAP0115 [Mycobac-
terium avium subsp. paratuberculosis K-10], YP_879405.1:
hypothetical protein MAV_0109 [Mycobacterium avium 104],
NZ_ABIN01000160_P_8921: predicted protein sequence from M.
intracellulare genome, NOTNCBI_FOR324_P_3844: predicted
protein sequence from M. fortuitum genome. Note: protein
sequences from M. marinum and M. ulcerans are shown in these
clusters, but peptides were not picked from these species. Amino
acid sequence is shown for each protein, with protein sequences
identified by NCBI accession number. Numbers under the clusters
indicate the amino acid number in the sequence; grey bars under
the clusters indicate the degree of similarity between the sequences
(high level bars = high level of similarity, low level bars = low
level of similarity).
(TIF)
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